Blair William & Co. IL Boosts Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Blair William & Co. IL grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 744,241 shares of the biotechnology company’s stock after purchasing an additional 757 shares during the quarter. Blair William & Co. IL owned approximately 0.23% of Exelixis worth $14,446,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asset Management L.P. raised its holdings in shares of Exelixis by 595.4% in the fourth quarter. Point72 Asset Management L.P. now owns 6,423,800 shares of the biotechnology company’s stock valued at $103,038,000 after buying an additional 5,500,100 shares during the last quarter. Norges Bank purchased a new position in shares of Exelixis in the 4th quarter valued at approximately $50,953,000. Assenagon Asset Management S.A. increased its holdings in shares of Exelixis by 67.9% in the first quarter. Assenagon Asset Management S.A. now owns 3,417,463 shares of the biotechnology company’s stock valued at $66,333,000 after purchasing an additional 1,381,656 shares during the period. State Street Corp lifted its holdings in shares of Exelixis by 10.7% during the second quarter. State Street Corp now owns 12,596,380 shares of the biotechnology company’s stock worth $262,257,000 after purchasing an additional 1,219,174 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Exelixis by 34.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 4,366,821 shares of the biotechnology company’s stock valued at $90,917,000 after buying an additional 1,116,580 shares during the last quarter. Institutional investors and hedge funds own 93.09% of the company’s stock.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $22.74 on Friday. Exelixis, Inc. has a 1 year low of $14.87 and a 1 year high of $22.80. The firm’s 50 day moving average price is $20.33 and its 200 day moving average price is $19.27. The firm has a market cap of $7.24 billion, a P/E ratio of 44.59, a price-to-earnings-growth ratio of 1.52 and a beta of 0.67.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.10. Exelixis had a return on equity of 6.53% and a net margin of 9.58%. The company had revenue of $469.85 million for the quarter, compared to analyst estimates of $448.59 million. As a group, equities analysts predict that Exelixis, Inc. will post 0.71 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Christopher J. Senner sold 60,000 shares of the stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $20.51, for a total transaction of $1,230,600.00. Following the transaction, the chief financial officer now directly owns 571,631 shares in the company, valued at approximately $11,724,151.81. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Christopher J. Senner sold 60,000 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $20.51, for a total transaction of $1,230,600.00. Following the completion of the sale, the chief financial officer now directly owns 571,631 shares in the company, valued at approximately $11,724,151.81. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Dana Aftab sold 4,600 shares of Exelixis stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $22.47, for a total value of $103,362.00. Following the completion of the transaction, the executive vice president now owns 399,943 shares in the company, valued at approximately $8,986,719.21. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 150,863 shares of company stock valued at $3,059,080. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Stifel Nicolaus upped their price objective on shares of Exelixis from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 2nd. Barclays decreased their price objective on shares of Exelixis from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Thursday, August 3rd. SVB Securities assumed coverage on shares of Exelixis in a research report on Tuesday, August 8th. They set a “market perform” rating and a $18.00 price target for the company. JMP Securities lifted their price objective on Exelixis from $24.00 to $27.00 and gave the stock an “outperform” rating in a report on Tuesday, August 22nd. Finally, Leerink Partnrs restated a “market perform” rating on shares of Exelixis in a research report on Tuesday, August 8th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and an average price target of $24.73.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.